Trial · NCT00656487

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

NCT00656487, Phase 2, Completed, The Scripps Research Institute; results first posted 2017-05-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults. Trials, record NCT00656487. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00656487

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT number: NCT00656487
Status: Completed
Phases: Phase 2
Enrollment: 66 participants, actual
Lead sponsor: The Scripps Research Institute
Conditions: Cannabis Dependence, Cannabis Withdrawal
Interventions: rimonabant, placebo
First posted: 2008-04-11
Last updated: 2017-06-19
Results first posted: 2017-05-15

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of Monitoring, During the Double-Blind Period	Day 28	The MWC is a 28-item instrument that is used to assess the severity of frequently reported cannabis withdrawal symptoms. Each item on the measure is recorded as a severity rating between 0-3 where a zero indicates not present and a three indicates severe. The severity rating of each item was summed to obtain a single marijuana withdrawal severity score ranging between 0- 84. A lower score indicates less severe withdrawal.
Primary	Plasma Norepinephrine	Day 28	Blood samples were obtained and plasma concentrations were determined using validated enzyme-linked immunosorbent assay (ELISA) techniques at 28 days following single dose administration of rimonabant or placebo, or commencement of monitoring, during the double-blind period.
Primary	Plasma Cortisol	Day 28	Blood samples were obtained and plasma concentrations were determined using validated enzyme-linked immunosorbent assay (ELISA) techniques at 28 days following single dose administration of rimonabant or placebo, or commencement of monitoring, during the double-blind period.
Primary	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Strategy Score at Day 28	Day 0 and Day 28	The CANTAB SWM task is a validated computer-based testing instrument assessing the memory component of executive function. Strategy Score is an estimate of use of the most efficient strategy to complete the task. Scores range from 8-56; higher scores equate to poor use of the most efficient strategy. Change = (Day 28 Score - Day 0 Score). A more negative result indicates greater improvement.
Primary	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Total Errors at Day 28	Day 0 and Day 28	The CANTAB SWM task is a validated computer-based testing instrument assessing the memory component of executive function. Total Errors are a measure of performance and are unbounded. Change = (Day 28 Score - Day 0 Score). A more negative result indicates greater improvement.
Primary	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Mean Time To First Response at Day 28	Day 0 and Day 28	The CANTAB SWM task is a validated computer-based testing instrument assessing the memory component of executive function. Mean Time To First Response is a measure of latency and is unbounded. Change = (Day 28 Time - Day 0 Time). A more negative result indicates greater improvement.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of Monitoring, During the Double-Blind Period	Day 28	One participant in the control group who completed monitoring during the double-blind portion of the trial did not complete a Marijuana Withdrawal Checklist at Day 28.	units on a scale	MEAN
PRIMARY	Plasma Norepinephrine	Day 28	Five control participants who completed the double blind / monitoring portion of the trial did not have samples available for analysis at Day 28. Two participants did not have blood drawn; two additional participant sample results were not returned by the laboratory; and one participant did not return a result due to an ELISA kit error.	ng/mL	MEAN
PRIMARY	Plasma Cortisol	Day 28	Two control participants and one placebo participant who completed the double blind / monitoring portion of the trial did not have samples available for analysis at Day 28. The control participants did not have blood drawn; the placebo participant returned a non-detectable value.	ug/dL	MEAN
PRIMARY	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Strategy Score at Day 28	Day 0 and Day 28		units on a scale	MEAN
PRIMARY	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Total Errors at Day 28	Day 0 and Day 28		units on a scale	MEAN
PRIMARY	Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Mean Time To First Response at Day 28	Day 0 and Day 28		milliseconds	MEAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of Monitoring, During the Double-Blind Period	Rimonabant	6.62	Standard Deviation 5.59	units on a scale
Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of Monitoring, During the Double-Blind Period	Placebo	6.68	Standard Deviation 7.87	units on a scale
Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of Monitoring, During the Double-Blind Period	Control	1.05	Standard Deviation 2.39	units on a scale
Plasma Norepinephrine	Rimonabant	2.12	Standard Deviation 1.14	ng/mL
Plasma Norepinephrine	Placebo	2.04	Standard Deviation 1.05	ng/mL
Plasma Norepinephrine	Control	1.75	Standard Deviation 0.84	ng/mL
Plasma Cortisol	Rimonabant	27.36	Standard Deviation 15.03	ug/dL
Plasma Cortisol	Placebo	19.29	Standard Deviation 7.42	ug/dL
Plasma Cortisol	Control	22.72	Standard Deviation 15.21	ug/dL
Change From Day 0 in Performance on the Cambridge Neuropsychological Test Automated Batteries Spatial Working Memory (CANTAB SWM) Strategy Score at Day 28	Rimonabant	-2.67	Standard Deviation 4.15	units on a scale

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Rimonabant	23
Overall Study	STARTED	Placebo	23
Overall Study	STARTED	Control	20
Overall Study	COMPLETED	Rimonabant	21
Overall Study	COMPLETED	Placebo	19
Overall Study	COMPLETED	Control	20
Overall Study	NOT COMPLETED	Rimonabant	2
Overall Study	NOT COMPLETED	Placebo	4
Overall Study	NOT COMPLETED	Control	0

Source ClinicalTrials.gov

Adverse events21

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Dyspepsia	Gastrointestinal disorders	Rimonabant	2	23
other	Dyspepsia	Gastrointestinal disorders	Placebo	0	23
other	Dyspepsia	Gastrointestinal disorders	Control	0	20
other	Nausea	Gastrointestinal disorders	Rimonabant	4	23
other	Nausea	Gastrointestinal disorders	Placebo	1	23
other	Nausea	Gastrointestinal disorders	Control	0	20
other	Fatigue	General disorders	Rimonabant	2	23
other	Fatigue	General disorders	Placebo	0	23
other	Fatigue	General disorders	Control	0	20
other	Nasopharyngitis	Infections and infestations	Rimonabant	0	23

1 to 10 of 21Source ClinicalTrials.gov

See all 21 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Rimonabant
Total, all-cause mortality	Placebo
Total, all-cause mortality	Control
Total, other adverse events	Rimonabant	10	23
Total, other adverse events	Placebo	10	23
Total, other adverse events	Control	4	20
Total, serious adverse events	Rimonabant	0	23
Total, serious adverse events	Placebo	0	23
Total, serious adverse events	Control	0	20

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P20DA024194	TRANSLATIONAL CTR ON THE CLINICAL NEUROBIOL OF CANNABIS ADDICTION	MASON, BARBARA J	SCRIPPS RESEARCH INSTITUTE, THE	NATIONAL INSTITUTE ON DRUG ABUSE	2007 to 2010

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00656487

GET https://conductscience.org/api/trials/v1/NCT00656487/events?page=2

API reference For AI assistants